The aim to present this study to highlight the therapeutic activity of vilentrole and fluticasone furate with dry powder inhaler device. Dry Powder Inhalers (Dpis) DPI are the drug–device combination products where the complexity of the formulation, its interaction with the device, and input from users play important roles in the drug delivery. As the landscape of DPI products advances with new powder formulations and novel device designs, understanding how these advancements impact performance can aid in developing generics that are therapeutically equivalent to the reference listed drug (RLD) products. This review details the current understanding of the formulation Fluticasone furate and vilenterole (FF/VI) and device related principles driving DPI performance, past and present research efforts to characterize these performance factors, and the implications that advances in formulation and device design may present for evaluating bioequivalence (BE) for generic development.
Impact Factor
2022: 6.012
This work is licensed under a